---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-054826"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2023-11-28T23:59:59+00:00"
generated_at: "2026-06-07T21:02:16.693022+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Roivant: IMVT-1402 600 mg Phase 1 data shows best-in-class potential; 74% IgG reduction

## Summary
- Four weekly SC doses of 600 mg IMVT-1402 reduced total IgG by mean 74%, similar to batoclimab's 76% reduction.
- Serum albumin and LDL-C at Day 29 showed no significant change from baseline (p>0.05), indicating placebo-like safety.
- Steady-state IgG reduction expected to reach ~80% with continued weekly dosing, matching batoclimab's timing of 6-8 weeks.
- Treatment was well tolerated with only mild or moderate adverse events observed.

## SEC filing metadata
- accession: 0001140361-23-054826
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2023-11-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036123054826/0001140361-23-054826-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036123054826/ef20015486_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-054826
- JSON: https://secwatch.observer/filing/0001140361-23-054826.json
- Plain text: https://secwatch.observer/filing/0001140361-23-054826.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.